Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
143
resultados
Última actualización
20/12/2024 [09:08:00]
Resumen de: US2024416034A1
A highly integrated drug infusion device, includes: a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply. A three dimensional circuit is provided on the case, and the three dimensional circuit is electrically connected to the power supply to supply power to the infusion device. The three dimensional circuit is arranged on the case and does not occupy the internal space of the infusion device, which can make the internal arrangement of the infusion device more compact and further reduce the volume of the infusion device.
Resumen de: US2024415450A1
Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time.
Resumen de: US2024415452A1
A computer-based method includes receiving, from a computer-based user interface, user-specified information about one or more events influential on the user's blood glucose level, generating, with a computer-based processor, a plurality of estimated trajectories of the user's blood glucose level as influenced by the one or more events, receiving a set of data that represents actual blood glucose measurements for the user, and identifying, with the computer-based processor, which of the estimated trajectories represents a best fit to the set of data that represents the actual blood glucose measurements for the user. At least some of the actual blood glucose measurements occurred later in time than a start time of the one or more events influential on the user's blood glucose level. A computer-based system is provided for implementing the method.
Resumen de: US2024415420A1
A method of providing behavioral information for glucose level control according to an embodiment of the present disclosure includes: acquiring subject glucose level data corresponding to a hypoglycemic range through an analyte monitoring device; acquiring target glucose level data belonging to a normal glucose level range; acquiring a trained neural network model that calculates the behavioral information for changing a glucose level value corresponding to the hypoglycemic range to the normal glucose level range; acquiring the behavioral information including at least one of a type and amount of food to be consumed by a user from the subject glucose level data and the target glucose level data using the trained neural network model; and outputting the behavioral information through the user terminal device.
Resumen de: US2024415422A1
A glucose monitoring device includes a housing configured to be placed on a skin surface of a user. The glucose monitoring device includes sensor electronics arranged within the housing. The glucose monitoring device further includes a glucose sensor that includes a first portion configured to be placed under the skin surface of the user for measuring signals indicative of glucose in a bodily fluid and a second portion configured to be arranged above the skin surface and that is coupled to the sensor electronics. The glucose monitoring device further includes a strain gauge disposed on the first portion and configured to detect a strain applied to the first portion.
Resumen de: US2024415416A1
A voltage measurement type glucose sensor comprises a microneedle array including a flat part and a plurality of microneedles located on one surface of the flat part; an enzyme layer located on a surface of the plurality of microneedles and including glucose oxidase; a supercapacitor located on the other side of the flat part; and a wireless communication module electrically connected to the supercapacitor, and a glucose measurement method using the same. The glucose sensor is self-driving without the need to apply separate external power, improving the lifespan of the device and enabling close monitoring of accurate glucose levels in real time,
Resumen de: US2024415423A1
According to various embodiments of this disclosure, a device for glucose monitoring is provided, the device comprising: a body-attachable unit, the body-attachable unit comprising: a housing; a sensor configured to measure an analyte concentration in the tissue; an adhesive patch disposed on the bottom side of the housing; and a release member protecting an adhesive surface of the adhesive patch. The device further comprises an applicator configured to contain the body-attachable unit and drive the body-attachable unit such that at least a portion of the sensor is inserted into the body of the user, with the applicator comprising: a case that includes an opening for receiving the body-attachable unit; and a cap detachably coupled to the case to cover at least a portion of the opening. In this configuration, the release member is configured to be separated from the adhesive patch upon detachment of the cap from the case.
Resumen de: US2024415421A1
One embodiment may provide a method for calibrating sensitivity for glucose measurement, the method comprising: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; determining a second sensitivity from the first sensitivity and a predetermined sensitivity depending on a sensor; determining a third sensitivity by adjusting the second sensitivity based on reliability of the first sensitivity that is based on a difference between the first sensitivity and a previous sensitivity; determining a fourth sensitivity from the third sensitivity based on whether a glucose value obtained from the offset value and the third sensitivity is within a specific range; and determining the fourth sensitivity as the sensitivity.
Resumen de: AU2023283678A1
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Resumen de: EP4477147A1
One embodiment may provide a method for calibrating sensitivity for glucose measurement, the method comprising: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; determining a second sensitivity from the first sensitivity and a predetermined sensitivity depending on a sensor; determining a third sensitivity by adjusting the second sensitivity based on reliability of the first sensitivity that is based on a difference between the first sensitivity and a previous sensitivity; determining a fourth sensitivity from the third sensitivity based on whether a glucose value obtained from the offset value and the third sensitivity is within a specific range; and determining the fourth sensitivity as the sensitivity.
Resumen de: EP4477148A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4477146A1
A method of providing behavioral information for glucose level control according to an embodiment of the present disclosure includes: acquiring subject glucose level data corresponding to a hypoglycemic range through an analyte monitoring device; acquiring target glucose level data belonging to a normal glucose level range; acquiring a trained neural network model that calculates the behavioral information for changing a glucose level value corresponding to the hypoglycemic range to the normal glucose level range; acquiring the behavioral information including at least one of a type and amount of food to be consumed by a user from the subject glucose level data and the target glucose level data using the trained neural network model; and outputting the behavioral information through the user terminal device.
Resumen de: WO2024250121A2
Provided are computer-implemented methods, systems and devices for generating a type-II (T2DM) diabetic status prediction, including: extracting voice biomarker feature values from the voice sample for predetermined voice biomarker features; determining the T2DM diabetic status prediction for the subject based on the biomarker feature values and the diabetic status prediction model; and outputting the T2DM diabetic status prediction for the subject. Provided are computer-implemented methods, systems and devices for generating a diabetic status model for predicting a T2DM diabetic status, including: diabetic status labels identifying a corresponding diabetic status for training subjects; and voice samples collected from the training subjects at different time points, each of the voice samples associated with a corresponding diabetic status label; determining voice feature values for corresponding voice features for each of the voice samples in the voice samples; and generating the diabetic status model based on the voice samples and the voice feature values.
Resumen de: AU2023281065A1
Systems, methods, and devices relate, generally, to autonomous dose injection. Durable dose, injection device may include a chamber, a drive mechanism, a logic circuit, and an actuator. The chamber may be to receive a prefilled insulin cartridge. The drive mechanism may be to apply force to a plunger of a received prefilled insulin cartridge, the plunger arranged to move within the received cartridge responsive to force applied by the drive mechanism and thereby push fluid in the received cartridge toward an interface for dispensing fluid. The logic circuit may be to receive analyte data for the user and calculate a target amount of insulin to deliver to a user. The dose ready confirmation actuator may be for the user to actuate to cause the delivery of insulin to the user.
Resumen de: US2024408303A1
Disclosed herein are systems and methods for providing an alert to a user when preservative values in insulin formulations are expected to be low. Variables that affect preservative loss in insulin can be tracked by an insulin pump while insulin is being delivered by the pump. If the variables indicate that preservative values are below a threshold, an alert can be provided on the pump instructing the user to replace the insulin and/or implement another corrective action.
Resumen de: US2024408304A1
A device for delivering medicament to a user is disclosed. The device comprises a reservoir for storing medicament; an infusion catheter fluidly communicating with the reservoir to deliver the medicament into a subcutaneous layer of the user: a pump fluidly communicating with the reservoir and infusion catheter for pumping the medicament from the reservoir though the infusion catheter: an introducer needle movable within the infusion catheter, the introducer needle configured to facilitate (a) insertion of the infusion catheter into a subcutaneous layer of the user and (b) retraction of the introducer needle after insertion of the infusion catheter to enable delivery of medicament through the infusion catheter; and a sensor for continuously monitoring glucose level in the user, wherein the sensor is configured to (a) engage the introducer needle and/or the infusion catheter and (b) simultaneously advance along with the infusion catheter during the insertion into the subcutaneous layer of the user by the introducer needle.
Resumen de: US2024407735A1
A method for predicting gestational diabetes mellitus (GDM) is provided. The method includes, at a continuous analyte monitoring (CAM) system, measuring at least glucose concentration levels of a user, generating sensor data packages based on the measured glucose concentration levels, and transmitting the sensor data packages. The method also includes, at a computing device, receiving the sensor data packages from the CAM system, determining a glucose feature combination from the measured glucose concentration levels, and generating a GDM prediction based on the glucose feature combination. The method may also include generating a quantitative GDM risk value based on the glucose feature combination. The quantitative GDM risk value has a range from a minimum risk value to a maximum risk value.
Resumen de: US2024407736A1
A system and method to provide guidance for diabetes therapy includes determining glycemic risks based on an analysis of glucose data. The analysis includes visualization of a glucose median, the variability of glucose in a patient, and the risk of hypoglycemia. An Advanced Daily Patterns report includes a visualization of an ambulatory glucose profile and a glucose control measure. The glucose control measure provides a highly visible and understandable display of the glucose condition of a patient visually expressed in the categories of low glucose, median glucose, and glucose variability.
Resumen de: US2024407680A1
Analyte sensor for use in medical devices for measuring analyte data such as glucose data, including: a power source providing electrical power to the analyte sensor, an enclosure of the analyte sensor, a sensor circuit powered by the power source and including two electrodes, wherein the electrodes each have a first portion that lies inside the enclosure and a second portion that lies outside of the enclosure. At least one protection unit is electrically coupled to the first portion of each of the two electrodes located inside the enclosure, wherein the at least one protection unit is configured to short-circuit the two electrodes in case a voltage signal from the sensor circuit applied to the electrodes exceeds a predetermined voltage threshold. A method for operating an analyte sensor is also disclosed.
Resumen de: US2024407676A1
Provided is an electronic device 100 including a sensor unit 130 configured to acquire a pulse wave of a subject and a controller 143 configured to estimate, using an estimation formula created based on a preprandial blood glucose level and a postprandial pulse wave and blood glucose level, an amount of change in the blood glucose level of the subject due to meal based on a postprandial pulse wave of the subject acquired by the sensor unit 130 and to estimate a postprandial blood glucose level of the subject based on the estimated amount of change and the preprandial blood glucose level of the subject.
Resumen de: US2024410905A1
A novel method of predicting life expectancy in persons, in particular in persons that have an a priori reduced life expectancy, for instance if they suffer from ischemic heart disease (IHD). IHD-related depression, ANSD, type 2 diabetes mellitus is provided. Also disclosed is a related method for increasing life expectancy in human subjects, in particular in human subjects having an a priori reduced life expectancy. The disclosure also provides a method for evaluating the efficacy of drugs other treatment of ANSD. The present invention also provides a novel method for diagnosing and treating/preventing type 2 diabetes mellitus or IHD-related depression. Finally, the disclosure also provides a method for diagnosing autonomic homeostatic glucose dysregulation, and a novel method to re-establish normal homeostatic function, if disrupted, dysregulated or insufficient.
Resumen de: US2024409978A1
The present application discloses an enzymatic electrode system and its applications. The enzymatic electrode system comprises a working electrode, a counter electrode, and an optional reference electrode. The working electrode includes an electrode support substrate and a conductive substrate located at the top of the electrode support substrate. The surface or interior of the conductive substrate contains oxidoreductases, coenzyme reductases, and optional coenzymes. This application utilizes a comprehensive enzymatic electrode system incorporating oxidoreductases, coenzyme reductases, and coenzymes for the detection of specific substances in samples, such as glucose, lactate, ketones, and the like.
Resumen de: US2024412863A1
A method of administering insulin includes receiving glucose measurements of a patient at a data processing device from a continuous glucose monitoring system. The glucose measurements are separated by a time interval. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments. The selection is based on the glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program, a subcutaneous program without meal boluses, a meal-by-meal subcutaneous program without carbohydrate counting, a meal-by-meal subcutaneous program with carbohydrate counting, and a subcutaneous program for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.
Resumen de: WO2024254501A1
A method for predicting gestational diabetes mellitus (GDM) is provided. The method includes, at a continuous analyte monitoring (CAM) system, measuring at least glucose concentration levels of a user, generating sensor data packages based on the measured glucose concentration levels, and transmitting the sensor data packages. The method also includes, at a computing device, receiving the sensor data packages from the CAM system, determining a glucose feature combination from the measured glucose concentration levels, and generating a GDM prediction based on the glucose feature combination. The method may also include generating a quantitative GDM risk value based on the glucose feature combination. The quantitative GDM risk value has a range from a minimum risk value to a maximum risk value.
Nº publicación: WO2024254437A1 12/12/2024
Solicitante:
TANDEM DIABETES CARE INC [US]
TANDEM DIABETES CARE, INC
Resumen de: WO2024254437A1
Disclosed herein are systems and methods for providing an alert to a user when preservative values in insulin formulations are expected to be low. Variables that affect preservative loss in insulin can be tracked by an insulin pump while insulin is being delivered by the pump. If the variables indicate that preservative values are below a threshold, an alert can be provided on the pump instructing the user to replace the insulin and/or implement another corrective action.
BOPI
Sede Electrónica
